期刊文献+

左炔诺孕酮微球有关物质测定方法研究

Determination of Related Substances in Levonorgestrel Microspheres
原文传递
导出
摘要 目的建立高效液相色谱(HPLC)测定左炔诺孕酮微球中的有关物质。方法采用Waters Symmetry Shield RP8(4.6 mm×250 mm,5μm)色谱柱;以甲醇-乙腈-水(体积比100∶266∶500)为流动相,等度洗脱,流速1.2 mL·min^(-1);柱温40℃;检测波长220 nm;进样量50μL。结果左炔诺孕酮峰与相邻杂质峰及各相邻杂质峰之间均能达到良好的分离,微球辅料对有关物质测定无影响;左炔诺孕酮的定量限为2.73 ng,检测限为1.4 ng;在0.07544~9.053μg·mL^(-1)范围内,相关系数为1.0000(n=8);重复性实验测定杂质总量的相对标准偏差(RSD)为7.5%(n=6)。结论本方法专属性强,灵敏度高,可用于左炔诺孕酮微球的质量控制。 OBJECTIVE To establish an isocratic elution method for determination of related substances of levonorgestrel microspheres.METHODS A C8 column(Waters Symmetry Shield RP84.6 mm×250 mm,5μm)was used.The mobile phase consisted of methanol-acetonitrile-water(100∶266∶500)and was eluted at the flow rate of 1.2 mL·min^(-1)and the column temperature was maintained at 40℃.The detection wavelength was set at 220 nm and the sample volume was 50μL.RESULTS Levonorgestrel,near peaks and other impurities were well separated from each other.All excipients of levonorgestrel microspheres did not influence the determination of related substance.The LOQ and LOD of levonorgestrel were 2.73 ng and 1.4 ng,respectively.The linearity of levonorgestrel ranged from 0.07544 to 9.053μg·mL^(-1)with a correlation coefficient of 1.0000(n=8).The repeatability RSD of total related substances(n=6)was 7.5%.CONCLUSION The proposed method shows high specify,accuracy and sensibility.It can be used for the quality control of levonorgestrel microspheres.
作者 李丹 宋冬梅 江文明 金薇 乐健 LI Dan;SONG Dong-mei;JIANG Wen-ming;JIN Wei;LE Jian(NMPA Key Laboratory for Quality Analysis of Chemical Drug Preparations,Shanghai Institutes for Food and Drug Control,Shanghai 201203,China)
出处 《中国药学杂志》 CAS CSCD 北大核心 2023年第13期1205-1209,共5页 Chinese Pharmaceutical Journal
关键词 左炔诺孕酮 微球 高效液相色谱法 杂质测定 levonorgestrel microsphere HPLC impurity determination
  • 相关文献

参考文献7

二级参考文献43

  • 1Wang J, Wang B M ,Schwendeman S P. Characterization of the initial burst release of a model peptide from poly(d, I-lactide-co-glycolide)microspheres[J].J Control Release 2002,82(2-3):289-307
  • 2Takenaga M, Yamaguchi Y, Kitagawa A, et al. A novel sustained-release formulation of insulin with dramatic reduction in initial rapid release[J]. J Control Release,2002,79(1-3):81-91.
  • 3Boury F, Marchais H, Proust J E,et al. Bovine serum albumin release from poly (α-hydroxy acid) microspheres: effects of polymer molecular weight and surface properties[J]. J Control Release, 1997,45(1) :75-86.
  • 4Bittner B ,Morlock M ,Koll H ,et al. Recombinant human erythropoietin(rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics[J]. Eur J Pharm Biopharm, 1998,45(3):295-305.
  • 5Kim H K,Park T O. Microencapsulation of Human Growth Hormone within biodegradable polyester microspheres: protein aggregation stability and incomplete release mechanism[J].Biotechnol Bioeng, 1999,65(6):660-667.
  • 6Jiang G, Woo B H, Kang F, et al. Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly (d, 1-Lactice-co-glycolide) microsphercs[J]. J Coatrol Release,2002,79(1-3):137-145
  • 7Sandor M, Enscore D, Weston P, et al. Effect of protein molecular weight on release from micron-sized PLGA microspheres[J].J Control Release,2001,76(3):297-311
  • 8Faisant N,Siepmann J,Benoit J P. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release[J].Eur J Pharm Sci,2002,15(4):355-366
  • 9Takada S,Kurokawa T,Miyazaki K,et al. Utilization of an amorphous form of a water-soluble GP Ⅱb/Ⅱa antagonist for controlled release from biodegradable microspheres[J].Pharm Res,1997,14(9):1146-1150
  • 10Walter E,Dreher D,Kok M,et al. Hydrophilic poly(d,1-Lactice-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells[J]. J Control Release, 2001,76(1-2) : 149-168.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部